BioXcel Therapeutics entered into a Fourteenth Amendment to its Credit Agreement on August 24, 2026, securing $1.25 million in additional term loans and paying a $250,000 upfront fee (20% of principal). The amendment reduced the minimum liquidity covenant from $3.0 million to $250,000 but imposed stricter restrictions on out-licensing intellectual property and asset sales. The company must enter into definitive agreements by August 31, 2026, to repay all obligations or secure alternative capital acceptable to lenders. BioXcel Therapeutics operates in the biotechnology industry, focusing on drug discovery and development.
